$1.95 Billion is the total value of Boxer Capital, LLC's 74 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 18.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | Mirati Therapeutics Inc. | $164,440,000 | -43.9% | 2,000,000 | 0.0% | 8.45% | -25.8% | |
| SWTX | Springworks Therapeutics Inc | $117,164,000 | -8.9% | 2,075,905 | 0.0% | 6.02% | +20.5% | |
| ITOS | Sell | iTeos Therapeutics Inc | $102,720,000 | -49.2% | 3,192,058 | -26.5% | 5.28% | -32.8% |
| BGNE | BeiGene Ltdsponsored adr | $94,300,000 | -30.4% | 500,000 | 0.0% | 4.85% | -7.9% | |
| RVMD | Revolution Medicines Inc | $88,884,000 | +1.4% | 3,484,264 | 0.0% | 4.57% | +34.1% | |
| RLAY | Relay Therapeutics Inc | $79,887,000 | -2.5% | 2,669,132 | 0.0% | 4.11% | +29.0% | |
| CYTK | Cytokinetics Inc | $77,301,000 | -19.2% | 2,100,000 | 0.0% | 3.97% | +6.9% | |
| PMVP | Buy | PMV Pharmaceuticals Inc | $72,842,000 | +11.1% | 3,498,636 | +23.3% | 3.74% | +47.1% |
| Tyra Biosciences Inc | $68,997,000 | -24.0% | 6,448,359 | 0.0% | 3.55% | +0.6% | ||
| APLS | New | Apellis Pharmaceuticals Inc | $66,241,000 | – | 1,303,700 | +100.0% | 3.40% | – |
| RXDX | New | Prometheus Biosciences Inc | $64,721,000 | – | 1,714,000 | +100.0% | 3.33% | – |
| XBI | Sell | SPDR SER TRs&p biotech | $62,916,000 | -74.5% | 700,000 | -68.2% | 3.23% | -66.2% |
| Tango Therapeutics Inc | $52,087,000 | -30.7% | 6,871,642 | 0.0% | 2.68% | -8.3% | ||
| MRUS | Merus NV | $50,236,000 | -16.9% | 1,900,000 | 0.0% | 2.58% | +10.0% | |
| RCUS | Arcus Biosciences Inc | $45,200,000 | -22.0% | 1,432,200 | 0.0% | 2.32% | +3.2% | |
| RETA | New | Reata Pharmaceuticals Inccl a | $40,590,000 | – | 1,239,000 | +100.0% | 2.09% | – |
| SAGE | Sage Therapeutics Inc | $36,211,000 | -22.2% | 1,094,000 | 0.0% | 1.86% | +2.9% | |
| BPMC | Blueprint Medicines Corp | $32,411,000 | -40.4% | 507,374 | 0.0% | 1.67% | -21.1% | |
| IOVA | Buy | Iovance Biotherapeutics Inc | $32,220,000 | +53.4% | 1,935,133 | +75.9% | 1.66% | +102.9% |
| ANAB | AnaptysBio Inc | $32,162,000 | -28.8% | 1,300,000 | 0.0% | 1.65% | -5.8% | |
| ACAD | Buy | Acadia Pharmaceuticals Inc | $30,574,000 | +608.1% | 1,263,930 | +583.2% | 1.57% | +835.1% |
| New | Amylyx Pharmaceuticals Inc | $28,270,000 | – | 2,200,000 | +100.0% | 1.45% | – | |
| IDYA | Ideaya Biosciences Inc | $24,649,000 | -52.7% | 2,202,812 | 0.0% | 1.27% | -37.3% | |
| RCKT | Rocket Pharmaceuticals Inc | $23,252,000 | -27.3% | 1,466,051 | 0.0% | 1.20% | -3.9% | |
| NUVB | Nuvation Bio Inc | $22,834,000 | -38.1% | 4,341,009 | 0.0% | 1.17% | -18.1% | |
| BLU | Bellus Health Inc | $22,016,000 | -14.5% | 3,200,000 | 0.0% | 1.13% | +13.2% | |
| FOLD | Amicus Therapeutics Inc | $22,018,000 | -18.0% | 2,325,000 | 0.0% | 1.13% | +8.5% | |
| GOSS | Gossamer Bio Inc | $21,373,000 | -23.3% | 2,462,358 | 0.0% | 1.10% | +1.6% | |
| KNTE | Kinnate Biopharma Inc | $20,804,000 | -36.5% | 1,847,559 | 0.0% | 1.07% | -16.0% | |
| RNA | Avidity Biosciences Inc | $20,711,000 | -22.3% | 1,121,327 | 0.0% | 1.06% | +2.8% | |
| PNT | Point Biopharma Global Inc | $19,925,000 | +42.3% | 2,500,000 | 0.0% | 1.02% | +88.2% | |
| FATE | Fate Therapeutics Inc | $19,385,000 | -33.7% | 500,000 | 0.0% | 1.00% | -12.3% | |
| GHRS | GH Research PLCordinary shares | $18,535,000 | -21.6% | 1,013,399 | 0.0% | 0.95% | +3.8% | |
| XENE | Xenon Pharmaceuticals Inc | $18,342,000 | -2.1% | 600,000 | 0.0% | 0.94% | +29.5% | |
| NRIX | Nurix Therapeutics Inc | $17,161,000 | -51.6% | 1,224,892 | 0.0% | 0.88% | -35.9% | |
| Nuvalent Inc | $16,810,000 | -27.0% | 1,210,192 | 0.0% | 0.86% | -3.5% | ||
| RARE | Ultragenyx Pharmaceutical Inc | $14,524,000 | -13.6% | 200,000 | 0.0% | 0.75% | +14.2% | |
| MIST | Milestone Pharmaceuticals Inc | $14,373,000 | -2.0% | 2,238,861 | 0.0% | 0.74% | +29.6% | |
| DAWN | Day One Biopharmaceuticals Inc | $11,804,000 | -41.1% | 1,189,943 | 0.0% | 0.61% | -22.1% | |
| AKRO | Akero Therapeutics Inc | $11,799,000 | -32.9% | 831,495 | 0.0% | 0.61% | -11.3% | |
| CNTA | Centessa Pharmaceuticals PLCsponsored ads | $11,273,000 | -20.0% | 1,251,137 | 0.0% | 0.58% | +5.9% | |
| CGEM | Cullinan Oncology Inc | $11,246,000 | -32.1% | 1,074,082 | 0.0% | 0.58% | -10.2% | |
| PRTA | Prothena Corp PLC | $10,971,000 | -26.0% | 300,000 | 0.0% | 0.56% | -2.1% | |
| TPTX | New | Turning Point Therapeutics Inc | $10,740,000 | – | 400,000 | +100.0% | 0.55% | – |
| Theseus Pharmaceuticals Inc | $10,285,000 | -9.1% | 892,057 | 0.0% | 0.53% | +20.5% | ||
| New | 2Seventy Bio Inc | $7,845,000 | – | 459,836 | +100.0% | 0.40% | – | |
| NGM | NGM Biopharmaceuticals Inc | $7,625,000 | -13.9% | 500,000 | 0.0% | 0.39% | +14.0% | |
| BCEL | Atreca Inc | $6,981,000 | +4.6% | 2,202,333 | 0.0% | 0.36% | +38.6% | |
| SLDB | Buy | Solid Biosciences Inc | $6,403,000 | +15.1% | 5,336,031 | +67.9% | 0.33% | +52.3% |
| RAIN | Rain Therapeutics Inc | $5,957,000 | -60.6% | 1,175,000 | 0.0% | 0.31% | -48.0% | |
| ORIC | Buy | Oric Pharmaceuticals Inc | $5,628,000 | +91.4% | 1,054,000 | +427.0% | 0.29% | +153.5% |
| BDTX | Black Diamond Therapeutics Inc | $5,581,000 | -48.0% | 2,014,858 | 0.0% | 0.29% | -31.2% | |
| ODT | Odonate Therapeutics Inc | $5,553,000 | -2.2% | 4,207,086 | 0.0% | 0.28% | +29.0% | |
| CDAK | Codiak Biosciences Inc | $5,330,000 | -43.7% | 850,065 | 0.0% | 0.27% | -25.5% | |
| BMEA | Biomea Fusion Inc | $5,300,000 | -40.1% | 1,188,405 | 0.0% | 0.27% | -20.9% | |
| BLSA | BCLS Acquisition Corp | $4,935,000 | +0.7% | 500,000 | 0.0% | 0.25% | +33.7% | |
| PANA | Panacea Acquisition Corp II | $4,875,000 | +0.5% | 500,000 | 0.0% | 0.25% | +33.5% | |
| EPIX | Essa Pharma Inc | $4,485,000 | -56.4% | 724,500 | 0.0% | 0.23% | -42.2% | |
| EQRX Inc | $4,130,000 | -39.4% | 1,000,000 | 0.0% | 0.21% | -20.0% | ||
| SELB | Selecta Biosciences Inc | $4,039,000 | -62.3% | 3,284,072 | 0.0% | 0.21% | -50.0% | |
| HSAQ | Health Sciences Acq Corp II | $3,964,000 | -1.7% | 400,000 | 0.0% | 0.20% | +29.9% | |
| BCAB | BioAtla Inc | $3,452,000 | -74.4% | 686,347 | 0.0% | 0.18% | -66.2% | |
| DBVT | DBV Technologies SAsponsored adr | $3,394,000 | -0.6% | 2,134,598 | 0.0% | 0.17% | +30.8% | |
| ALGS | Aligos Therapeutics Inc | $3,281,000 | -81.9% | 1,526,048 | 0.0% | 0.17% | -76.0% | |
| ELEV | Elevation Oncology Inc | $2,199,000 | -58.1% | 872,780 | 0.0% | 0.11% | -44.6% | |
| OMEG | Omega Alpha SPACcl a | $1,964,000 | +0.5% | 200,000 | 0.0% | 0.10% | +32.9% | |
| GMTX | Gemini Therapeutics Inc | $1,807,000 | -52.2% | 1,300,000 | 0.0% | 0.09% | -36.7% | |
| MEIP | MEI Pharma Inc | $1,755,000 | -77.4% | 2,913,091 | 0.0% | 0.09% | -70.2% | |
| GNCA | Genocea Biosciences Inc | $1,418,000 | +7.8% | 1,134,453 | 0.0% | 0.07% | +43.1% | |
| CABA | Cabaletta Bio Inc | $1,096,000 | -46.5% | 540,000 | 0.0% | 0.06% | -30.0% | |
| TARA | Protara Therapeutics Inc | $1,069,000 | -24.3% | 209,227 | 0.0% | 0.06% | 0.0% | |
| NUVBWS | Nuvation Bio Inc*w exp 07/07/202 | $203,000 | -59.7% | 266,666 | 0.0% | 0.01% | -50.0% | |
| New | Bellicum Pharmaceuticals Inc | $123,000 | – | 56,950 | +100.0% | 0.01% | – | |
| New | Surrozen Inc*w exp 08/01/203 | $17,000 | – | 66,666 | +100.0% | 0.00% | – | |
| Exit | Surrozen Inc | $0 | – | -200,000 | -100.0% | -0.05% | – | |
| HLXA | Exit | Helix Acquisition Corp | $0 | – | -400,000 | -100.0% | -0.15% | – |
| RACB | Exit | Research Alliance Corp II | $0 | – | -500,000 | -100.0% | -0.19% | – |
| JYAC | Exit | JIYA Acquisition Corp | $0 | – | -500,000 | -100.0% | -0.19% | – |
| Exit | SPDR SER TRcall | $0 | – | -550,000 | -100.0% | -2.39% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.